Search

Displaying results 6521 - 6530 of 10000 in total
  1. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.

  2. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants). … AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  3. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258] … WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC).

  4. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

    Products: DOIZ 50 MG FC TABLET, Itomed 50 mg Filmtabletten
  5. Drug

    SRD-001

    go.drugbank.com/drugs/DB25902
    Investigational

    SRD-001 is under investigation in clinical trial NCT06224660 (Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy).

  6. Drug

    Suvecaltamide

    go.drugbank.com/drugs/DB19139
    Investigational

    Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

  7. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  8. Drug

    Resiniferatoxin

    go.drugbank.com/drugs/DB06515
    Investigational

    of physiological pain). … Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission

  9. Drug

    Bencyclane

    go.drugbank.com/drugs/DB13488
    Experimental

    Its mechanism may involve block of calcium channels. … A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects.

  10. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).